These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23453766)

  • 41. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults.
    Talbot HK; Coleman LA; Crimin K; Zhu Y; Rock MT; Meece J; Shay DK; Belongia EA; Griffin MR
    Vaccine; 2012 Jun; 30(26):3937-3943. PubMed ID: 22484350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.
    Luytjes W; Enouf V; Schipper M; Gijzen K; Liu WM; van der Lubben M; Meijer A; van der Werf S; Soethout EC
    Vaccine; 2012 Jul; 30(35):5262-9. PubMed ID: 22691431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and sustainability of the immune response in Brazilian HIV-1-infected individuals vaccinated with inactivated triple influenza vaccine.
    Souza TM; Santini-Oliveira M; Martorelli A; Luz PM; Vasconcellos MT; Giacoia-Gripp CB; Morgado M; Nunes EP; Lemos AS; Ferreira AC; Moreira RI; Veloso VG; Siqueira M; Grinsztejn B; Camacho LA
    J Med Virol; 2016 Mar; 88(3):426-36. PubMed ID: 26267817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K; Dhitavat J; Thantamnu N; Kosoltanapiwat N; Auayporn M; Jiang L; Puthavathana P; Pitisuttithum P
    Vaccine; 2017 Dec; 35(52):7339-7346. PubMed ID: 29157960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
    BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease.
    Nath KD; Burel JG; Shankar V; Pritchard AL; Towers M; Looke D; Davies JM; Upham JW
    Int J Chron Obstruct Pulmon Dis; 2014; 9():51-6. PubMed ID: 24399872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
    Phongsamart W; Sirisanthana V; Wittawatmongkol O; Maleesatharn A; Sudjaritruk T; Chearskul P; Aurpibul L; Sirisanthana T; Chokephaibulkit K
    Vaccine; 2011 Nov; 29(47):8705-11. PubMed ID: 21893147
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The immunogenicity of intradermal influenza vaccination in COPD patients.
    Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
    Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association between Hemagglutinin Stem-Reactive Antibodies and Influenza A/H1N1 Virus Infection during the 2009 Pandemic.
    Hoa LNM; Mai LQ; Bryant JE; Thai PQ; Hang NLK; Yen NTT; Duong TN; Thoang DD; Horby P; Werheim HFL; Fox A
    J Virol; 2016 Jul; 90(14):6549-6556. PubMed ID: 27170747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.
    Jacobson RM; Grill DE; Oberg AL; Tosh PK; Ovsyannikova IG; Poland GA
    Hum Vaccin Immunother; 2015; 11(4):961-9. PubMed ID: 25835513
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.
    Torii Y; Kimura H; Ochi N; Kaneko K; Ando H; Kiuchi T; Ito Y
    Vaccine; 2011 Jun; 29(25):4187-9. PubMed ID: 21513762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn.
    Blanchard-Rohner G; Meier S; Bel M; Combescure C; Othenin-Girard V; Swali RA; Martinez de Tejada B; Siegrist CA
    Pediatr Infect Dis J; 2013 Dec; 32(12):1374-80. PubMed ID: 24569309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
    Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
    Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study.
    Adler S; Krivine A; Weix J; Rozenberg F; Launay O; Huesler J; Guillevin L; Villiger PM
    Rheumatology (Oxford); 2012 Apr; 51(4):695-700. PubMed ID: 22171015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
    de Lavallade H; Garland P; Sekine T; Hoschler K; Marin D; Stringaris K; Loucaides E; Howe K; Szydlo R; Kanfer E; Macdonald D; Kelleher P; Cooper N; Khoder A; Gabriel IH; Milojkovic D; Pavlu J; Goldman JM; Apperley JF; Rezvani K
    Haematologica; 2011 Feb; 96(2):307-14. PubMed ID: 20971824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.
    Liu W; Ma MJ; Tang F; He C; Zhang XA; Jiang LF; Xin DS; Hu CY; Looman C; Cao WC
    Vaccine; 2012 Jul; 30(32):4785-9. PubMed ID: 22633868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.